Finding experienced investigators for clinical trials remains one of the greatest obstacles to rapidly completing studies especially since protocol complexity continues to increase including increased patient eligibility criteria. This leads to an increased demand for experienced investigators who can evaluate studies appropriate for their site and reject those they will not be able to perform on.
ILS is an informatics driven company whose proprietary investigator database now contains over 27,000 experienced US investigators and 1200+ experienced Canadian investigators in all medical specialties and practice settings.

Investigators are targeted by multiple criteria including medical specialty, research experience, practice setting and location. Instant email broadcasts rapidly identify interested investigators with current capacity for additional trials matching client specifications. Site questionnaires are sent to further qualify investigators.

More sponsors and CROs use ILS

"In the last 12 months, despite the downturn in new trials, the number of sponsors and CROs using ILS to recruit investigators expanded significantly including 60 new projects in 2010" said Joe Bollert, Ph.D., president of ILS. "Sponsors and CROs, including 12 new clients in 2010, come to ILS for initial investigator recruitment, mid-project recruitment and rescue investigator recruitment. We can literally reach hundreds of investigators in any specialty in seconds and solicit their interest in a clinical trial. No one else has this type of instant access to such a large volume of experienced investigators."

Motivated and experienced investigators

The key to ILS’s success and repeat business from sponsors and CROs is that investigators who sign up through ILS are extra motivated to perform and experienced. Investigators agree to pay ILS a fee when the study launches and only sign up if they feel the study is a good match for their site. Importantly, ILS investigators typically have ten or more years of clinical research experience which allows careful consideration of studies being presented.